미국의 멀티오믹스 시장 규모, 점유율, 동향 분석 리포트 : 제품·서비스별, 유형별, 플랫폼별, 용도별, 최종 용도별, 부문 예측(2024-2030년)

U.S. Multiomics Market Growth & Trends:

The U.S. multiomics market size is anticipated to reach USD 2.90 billion by 2030 and is projected to grow at a CAGR of 15.55% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market growth can be attributed to various factors such as advancements in omics technology, increasing demand for personalized medicines, growing prevalence of chronic diseases, and rising application in drug discovery & development. This has led to an anticipation of increased demand for multiomics in the U.S. over the forecast period.

The COVID-19 pandemic has stimulated advancements in the U.S. multiomics industry, accelerating research, driving diagnostic innovations, and enhancing precision medicine. It has expedited drug discovery, promoted biobanking collaborations, and facilitated the integration of multiomics into telemedicine. Through comprehensive omics analysis, researchers gained insights into COVID-19 pathogenesis, aiding in the development of personalized healthcare solutions and bolstering infectious disease management efforts.

Moreover, multiomics, which is further fueled by AI, modernizes biomedical research by integrating data from genomics, proteomics, and metabolomics. Artificial intelligence algorithms analyze complex omics datasets to uncover molecular insights, identify biomarkers, and predict disease outcomes. This collaboration enhances the understanding of biological systems, accelerates drug discovery, and facilitates personalized healthcare approaches, marking a transformative shift in biomedical sciences. For instance, in May 2023, Google Cloud introduced two novel AI-driven solutions in life sciences for expediting drug discovery and precision medicine for biotech firms, pharmaceutical companies, and public sector entities. The Target and Lead Identification Suite supports researchers in identifying amino acid functionalities and forecasting protein structures, while the Multiomics Suite fast-tracks genomic data analysis and interpretation, empowering companies to devise tailored treatments effectively.

However, multiomics technologies often require substantial investment in equipment, software, and skilled personnel. High initial costs and ongoing expenses for data analysis and interpretation may limit adoption, particularly among smaller research institutions and healthcare facilities, thus hampering the growth of the market.

U.S. Multiomics Market Report Highlights:

• In terms of products & services, the product segment dominated the market in 2023 with the largest revenue share. This is due to the increasing demand for advanced technologies and tools for enabling the integration & analysis of diverse omics data sets. On the other hand, the services segment is anticipated to grow at the fastest CAGR over the forecast period.
• Based on type, the bulk multiomics segment held the largest market share in 2023. The various advantages of bulk multiomics can be attributed to the segment's dominance. Typically, bulk multiomics is essential for systematically explaining disorder pathogenesis and different phenotypes at the individual level.
• Based on platform, the genomics segment dominated the market in 2023 with a revenue share of 39.8%. This is attributed to the growing technological advancements and active investments in genomic research activities. On the other hand, the metabolomics segment is anticipated to grow at the fastest CAGR from 2024 to 2030, owing to the rising demand for personalized medicines.
• In terms of application, the oncology segment dominated the market in 2023 with a revenue share of 40.7%, and it is expected to grow at the fastest CAGR over the forecast period. The rising incidence of cancer and the growing use of multiomics for cancer are anticipated to drive segment growth.
• Based on end-use, academic & research institutes dominated the segment with a revenue share of 49.0% in 2023. This is attributed to the increasing studies and research focusing on multiomics approaches, including genomics, proteomics, metabolomics, and transcriptomics. On the other hand, pharmaceutical & biotechnology companies is anticipated to grow at the fastest CAGR from 2024 to 2030.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Product & Services Segment
  • 1.1.2. Type Segment
  • 1.1.3. Platform Segment
  • 1.1.4. Application Segment
  • 1.1.5. End-use Segment
• 1.2. Estimates and Forecast Timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Primary Research
• 1.5. Information or Data Analysis:
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objective

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. The increasing interest of researchers in the field of single-cell genomics
    • 3.2.1.2. Rising incidence of chronic diseases
    • 3.2.1.3. Technological advancements
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High initial costs
    • 3.2.2.2. Stringent government policies and regulations
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Product & Services Business Analysis

• 4.1. Product & Services Segment Dashboard
• 4.2. U.S. Multiomics Market Product & Services Movement Analysis
• 4.3. U.S. Multiomics Market Size & Trend Analysis, by Product & Services, 2018 to 2030 (USD Million)
• 4.4. Product
  • 4.4.1. Product market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4.2. Instruments
    • 4.4.2.1. Instruments market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4.3. Consumables
    • 4.4.3.1. Consumables market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4.4. Software
    • 4.4.4.1. Software market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.5. Services
  • 4.5.1. Services market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Type Business Analysis

• 5.1. Type Segment Dashboard
• 5.2. U.S. Multiomics Market Type Movement Analysis
• 5.3. U.S. Multiomics Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 5.4. Single-cell Multiomics
  • 5.4.1. Single-cell multiomics market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.5. Bulk Multiomics
  • 5.5.1. Bulk multiomics market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Platform Business Analysis

• 6.1. Platform Segment Dashboard
• 6.2. U.S. Multiomics Market Platform Movement Analysis
• 6.3. U.S. Multiomics Market Size & Trend Analysis, by Platform, 2018 to 2030 (USD Million)
• 6.4. Genomics
  • 6.4.1. Genomics market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.5. Transcriptomics
  • 6.5.1. Transcriptomics market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.6. Proteomics
  • 6.6.1. Proteomics market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.7. Metabolomics
  • 6.7.1. Metabolomics market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.8. Integrated Omics Platform
  • 6.8.1. Integrated omics platform market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Application Business Analysis

• 7.1. Application Segment Dashboard
• 7.2. U.S. Multiomics Market Application Movement Analysis
• 7.3. U.S. Multiomics Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 7.4. Cell Biology
  • 7.4.1. Cell biology market estimates and forecasts, 2018 - 2030 (USD Million)
• 7.5. Oncology
  • 7.5.1. Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
• 7.6. Neurology
  • 7.6.1. Neurology market estimates and forecasts, 2018 - 2030 (USD Million)
• 7.7. Immunology
  • 7.7.1. Immunology market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 8. End-Use Business Analysis

• 8.1. End-Use Segment Dashboard
• 8.2. U.S. Multiomics Market End-Use Movement Analysis
• 8.3. U.S. Multiomics Market Size & Trend Analysis, by End-Use, 2018 to 2030 (USD Million)
• 8.4. Academic & Research Institutes
  • 8.4.1. Academic & research institutes market estimates and forecasts, 2018 - 2030 (USD Million)
• 8.5. Pharmaceutical & Biotechnology Companies
  • 8.5.1. Pharmaceutical & biotechnology companies market estimates and forecasts, 2018 - 2030 (USD Million)
• 8.6. Others
  • 8.6.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2023
• 9.4. Company Profiles/Listing
  • 9.4.1. BD
    • 9.4.1.1. Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. Thermo Fisher Scientific Inc.
    • 9.4.2.1. Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. Illumina, Inc
    • 9.4.3.1. Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. Danaher
    • 9.4.4.1. Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. PerkinElmer Inc.
    • 9.4.5.1. Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. Shimadzu Corporation
    • 9.4.6.1. Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. Bruker
    • 9.4.7.1. Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. QIAGEN
    • 9.4.8.1. Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. Agilent Technologies, Inc.
    • 9.4.9.1. Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. BGI
    • 9.4.10.1. Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Strategic Initiatives